2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Thyroid Carcinoma, Anaplastic
4
Thyroid Neoplasms
3
Neuroendocrine Tumors
3
Neoplasms
3
Head and Neck Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
Everolimus
10
Octreotide
7
pasireotide
5
lanreotide
5
gallium Ga 68 dotatate
5
lutetium Lu 177 dotatate
3
cabozantinib
3
Sunitinib
3
Nivolumab
3
ganitumab
2
fluorodopa F 18
2
Temozolomide
2
Ga(III)-DOTATOC
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
zimberelimab
1
veliparib
1
telotristat ethyl
1
surufatinib
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
olaparib
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts